{"id":371638,"date":"2025-07-28T15:33:20","date_gmt":"2025-07-28T15:33:20","guid":{"rendered":"https:\/\/humainhealthcare.com\/?p=371638"},"modified":"2025-07-28T15:33:21","modified_gmt":"2025-07-28T15:33:21","slug":"fda-approves-triple-pill-for-hypertension-a-step-towards-minimally-disruptive-care","status":"publish","type":"post","link":"https:\/\/humainhealthcare.com\/fr\/fda-approves-triple-pill-for-hypertension-a-step-towards-minimally-disruptive-care\/","title":{"rendered":"FDA hyv\u00e4ksyy kolmoispillerin verenpainetautiin: askel kohti \"minimaalisesti h\u00e4iritsev\u00e4\u00e4 hoitoa\""},"content":{"rendered":"<p>Yhteenveto: Yhdysvaltain FDA on hyv\u00e4ksynyt Widaplikin, polypillerin, joka yhdist\u00e4\u00e4 telmisartaania (angiotensiini II -reseptorin salpaaja), amlodipiinia (kalsiumkanavan salpaaja) ja indapamidia (diureetti). T\u00e4m\u00e4 kerran p\u00e4iv\u00e4ss\u00e4 otettava l\u00e4\u00e4kemuoto pyrkii yksinkertaistamaan verenpainetaudin hoitoa ja parantamaan hoidon noudattamista.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">\ud83d\udccc Kliininen n\u00e4ytt\u00f6<\/h2>\n\n\n\n<p>\u2013 *The Lancet*-lehdess\u00e4 julkaistussa tutkimuksessa verrattiin polypilli\u00e4 erilaisiin kaksoishoitoihin. Tulokset osoittivat, ett\u00e4 kolmoishoito alensi systolista verenpainetta merkitt\u00e4v\u00e4sti enemm\u00e4n, eik\u00e4 haittavaikutukset, kuten hypo\/hypernatremia tai hypokalemia, lis\u00e4\u00e4ntyneet merkitt\u00e4v\u00e4sti.<\/p>\n\n\n\n<p>\u2013 *JACC*-lehdess\u00e4 julkaistussa tutkimuksessa, johon osallistui noin 300 liev\u00e4\u00e4 tai kohtalaista verenpainetautia sairastavaa potilasta, verenpaine saatiin hallintaan 65\u201370 % nelj\u00e4n viikon kuluttua nelj\u00e4nnes- tai puoliannoksella polypilli\u00e4 verrattuna 37 %:iin lumel\u00e4\u00e4keryhm\u00e4ss\u00e4 (keskim\u00e4\u00e4r\u00e4inen lasku 7\u20138 mmHg).<\/p>\n\n\n\n<p>\u2013 *JAMA Cardiology* -lehdess\u00e4 (2023) julkaistu meta-analyysi, joka kattoi seitsem\u00e4n tutkimusta ja noin 1 900 potilasta, vahvisti kolmoishoidon paremman verenpaineen alentamisessa ilman lis\u00e4\u00e4ntyneit\u00e4 haittavaikutuksia ja tukee sen k\u00e4ytt\u00f6\u00e4 tosiel\u00e4m\u00e4n tilanteissa.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">\ud83c\udfaf Kliininen vaikutus<\/h2>\n\n\n\n<p>Polypilleri tarjoaa yksinkertaisemman vaihtoehdon monimutkaisille hoito-ohjelmille ja edist\u00e4\u00e4 hoidon noudattamista kerran p\u00e4iv\u00e4ss\u00e4 tapahtuvan annostelun avulla. Kannattajat korostavat sen roolia \"minimaalisesti h\u00e4iritsev\u00e4ss\u00e4 l\u00e4\u00e4ketieteess\u00e4\". Asiantuntijat kuitenkin varoittavat, ett\u00e4 kliiniset tutkimukset keskittyiv\u00e4t keski-ik\u00e4isiin potilaisiin kontrolloiduissa ymp\u00e4rist\u00f6iss\u00e4, mik\u00e4 tekee sen todellisesta sovellettavuudesta i\u00e4kk\u00e4\u00e4mpiin tai monisairauksista potilaisiin rajoitettua.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">\ud83e\udde0 Teknologia ja terveys<\/h2>\n\n\n\n<p>Samaan aikaan Mayo Clinic Platform edist\u00e4\u00e4 teko\u00e4lyn k\u00e4ytt\u00f6\u00e4 reaalimaailman, monikeskustutkimuksen kliinisess\u00e4 datassa. Hy\u00f6dynt\u00e4m\u00e4ll\u00e4 standardoituja ja anonymisoituja terveystietoja t\u00e4m\u00e4 aloite nopeuttaa translationaalista tutkimusta ja tukee teko\u00e4lypohjaisten t\u00e4sm\u00e4l\u00e4\u00e4ketieteen mallien validointia.<\/p>","protected":false},"excerpt":{"rendered":"<p>Summary: The U.S. FDA has approved Widaplik, a polypill that combines telmisartan (an angiotensin II receptor blocker), amlodipine (a calcium channel blocker), and indapamide (a diuretic). This once-daily formulation aims to simplify hypertension treatment and improve adherence. \ud83d\udccc Clinical Evidence &#8211; A study published in *The Lancet* compared the polypill to various dual therapies. Results [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":371639,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"off","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[14],"tags":[],"class_list":["post-371638","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-geneva"],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.1.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"Summary: The U.S. FDA has approved Widaplik, a polypill that combines telmisartan (an angiotensin II receptor blocker), amlodipine (a calcium channel blocker), and indapamide (a diuretic). This once-daily formulation aims to simplify hypertension treatment and improve adherence. \ud83d\udccc Clinical Evidence - A study published in *The Lancet* compared the polypill to various dual therapies. Results\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"info@humainhealthcare.com\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/humainhealthcare.com\/fr\/fda-approves-triple-pill-for-hypertension-a-step-towards-minimally-disruptive-care\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.1.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"fr_FR\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Humain Healthcare: - Medical Treatment in\u00a0Barcelona\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"FDA Approves Triple Pill for Hypertension: A Step Towards \u2018Minimally Disruptive Care\u2019 - Humain Healthcare:\" \/>\n\t\t<meta property=\"og:description\" content=\"Summary: The U.S. FDA has approved Widaplik, a polypill that combines telmisartan (an angiotensin II receptor blocker), amlodipine (a calcium channel blocker), and indapamide (a diuretic). This once-daily formulation aims to simplify hypertension treatment and improve adherence. \ud83d\udccc Clinical Evidence - A study published in *The Lancet* compared the polypill to various dual therapies. Results\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/humainhealthcare.com\/fr\/fda-approves-triple-pill-for-hypertension-a-step-towards-minimally-disruptive-care\/\" \/>\n\t\t<meta property=\"og:image\" content=\"https:\/\/humainhealthcare.com\/wp-content\/uploads\/2025\/07\/twocaucasian.jpg\" \/>\n\t\t<meta property=\"og:image:secure_url\" content=\"https:\/\/humainhealthcare.com\/wp-content\/uploads\/2025\/07\/twocaucasian.jpg\" \/>\n\t\t<meta property=\"og:image:width\" content=\"1216\" \/>\n\t\t<meta property=\"og:image:height\" content=\"832\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2025-07-28T15:33:20+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2025-07-28T15:33:21+00:00\" \/>\n\t\t<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/HumainHealthcareBarcelone\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"FDA Approves Triple Pill for Hypertension: A Step Towards \u2018Minimally Disruptive Care\u2019 - Humain Healthcare:\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Summary: The U.S. FDA has approved Widaplik, a polypill that combines telmisartan (an angiotensin II receptor blocker), amlodipine (a calcium channel blocker), and indapamide (a diuretic). This once-daily formulation aims to simplify hypertension treatment and improve adherence. \ud83d\udccc Clinical Evidence - A study published in *The Lancet* compared the polypill to various dual therapies. Results\" \/>\n\t\t<meta name=\"twitter:image\" content=\"https:\/\/humainhealthcare.com\/wp-content\/uploads\/2025\/07\/twocaucasian.jpg\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/fda-approves-triple-pill-for-hypertension-a-step-towards-minimally-disruptive-care\\\/#blogposting\",\"name\":\"FDA Approves Triple Pill for Hypertension: A Step Towards \\u2018Minimally Disruptive Care\\u2019 - Humain Healthcare:\",\"headline\":\"FDA Approves Triple Pill for Hypertension: A Step Towards &#8216;Minimally Disruptive Care&#8217;\",\"author\":{\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/author\\\/infohumainhealthcare-com\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/humainhealthcare.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/image-3.png\",\"width\":1024,\"height\":1024},\"datePublished\":\"2025-07-28T15:33:20+00:00\",\"dateModified\":\"2025-07-28T15:33:21+00:00\",\"inLanguage\":\"fr-FR\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/fda-approves-triple-pill-for-hypertension-a-step-towards-minimally-disruptive-care\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/fda-approves-triple-pill-for-hypertension-a-step-towards-minimally-disruptive-care\\\/#webpage\"},\"articleSection\":\"Geneva\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/fda-approves-triple-pill-for-hypertension-a-step-towards-minimally-disruptive-care\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/category\\\/geneva\\\/#listItem\",\"name\":\"Geneva\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/category\\\/geneva\\\/#listItem\",\"position\":2,\"name\":\"Geneva\",\"item\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/category\\\/geneva\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/fda-approves-triple-pill-for-hypertension-a-step-towards-minimally-disruptive-care\\\/#listItem\",\"name\":\"FDA Approves Triple Pill for Hypertension: A Step Towards &#8216;Minimally Disruptive Care&#8217;\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/fda-approves-triple-pill-for-hypertension-a-step-towards-minimally-disruptive-care\\\/#listItem\",\"position\":3,\"name\":\"FDA Approves Triple Pill for Hypertension: A Step Towards &#8216;Minimally Disruptive Care&#8217;\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/category\\\/geneva\\\/#listItem\",\"name\":\"Geneva\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/#organization\",\"name\":\"Humain Healthcare\",\"description\":\"International medical services provider in Barcelona offering personalized diagnosis, treatment coordination, and access to top specialists for global patients.\",\"url\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/\",\"telephone\":\"+34611975260\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/humainhealthcare.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/WhatsApp-Image-2025-05-26-at-22.12.40_410869ab.jpg\",\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/fda-approves-triple-pill-for-hypertension-a-step-towards-minimally-disruptive-care\\\/#organizationLogo\",\"width\":1024,\"height\":1024},\"image\":{\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/fda-approves-triple-pill-for-hypertension-a-step-towards-minimally-disruptive-care\\\/#organizationLogo\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/HumainHealthcareBarcelone\",\"https:\\\/\\\/www.instagram.com\\\/humainhealthcare\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/author\\\/infohumainhealthcare-com\\\/#author\",\"url\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/author\\\/infohumainhealthcare-com\\\/\",\"name\":\"info@humainhealthcare.com\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/fda-approves-triple-pill-for-hypertension-a-step-towards-minimally-disruptive-care\\\/#authorImage\",\"url\":\"https:\\\/\\\/humainhealthcare.com\\\/wp-content\\\/litespeed\\\/avatar\\\/767cd8d416ab6b3ab02867bd8bcdbb54.jpg?ver=1790180516\",\"width\":96,\"height\":96,\"caption\":\"info@humainhealthcare.com\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/fda-approves-triple-pill-for-hypertension-a-step-towards-minimally-disruptive-care\\\/#webpage\",\"url\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/fda-approves-triple-pill-for-hypertension-a-step-towards-minimally-disruptive-care\\\/\",\"name\":\"FDA Approves Triple Pill for Hypertension: A Step Towards \\u2018Minimally Disruptive Care\\u2019 - Humain Healthcare:\",\"description\":\"Summary: The U.S. FDA has approved Widaplik, a polypill that combines telmisartan (an angiotensin II receptor blocker), amlodipine (a calcium channel blocker), and indapamide (a diuretic). This once-daily formulation aims to simplify hypertension treatment and improve adherence. \\ud83d\\udccc Clinical Evidence - A study published in *The Lancet* compared the polypill to various dual therapies. Results\",\"inLanguage\":\"fr-FR\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/fda-approves-triple-pill-for-hypertension-a-step-towards-minimally-disruptive-care\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/author\\\/infohumainhealthcare-com\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/author\\\/infohumainhealthcare-com\\\/#author\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/humainhealthcare.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/image-3.png\",\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/fda-approves-triple-pill-for-hypertension-a-step-towards-minimally-disruptive-care\\\/#mainImage\",\"width\":1024,\"height\":1024},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/fda-approves-triple-pill-for-hypertension-a-step-towards-minimally-disruptive-care\\\/#mainImage\"},\"datePublished\":\"2025-07-28T15:33:20+00:00\",\"dateModified\":\"2025-07-28T15:33:21+00:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/\",\"name\":\"Humain Healthcare:\",\"description\":\"Medical Treatment in\\u00a0Barcelona\",\"inLanguage\":\"fr-FR\",\"publisher\":{\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"FDA Approves Triple Pill for Hypertension: A Step Towards \u2018Minimally Disruptive Care\u2019 - Humain Healthcare:","description":"Summary: The U.S. FDA has approved Widaplik, a polypill that combines telmisartan (an angiotensin II receptor blocker), amlodipine (a calcium channel blocker), and indapamide (a diuretic). This once-daily formulation aims to simplify hypertension treatment and improve adherence. \ud83d\udccc Clinical Evidence - A study published in *The Lancet* compared the polypill to various dual therapies. Results","canonical_url":"https:\/\/humainhealthcare.com\/fr\/fda-approves-triple-pill-for-hypertension-a-step-towards-minimally-disruptive-care\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/humainhealthcare.com\/fr\/fda-approves-triple-pill-for-hypertension-a-step-towards-minimally-disruptive-care\/#blogposting","name":"FDA Approves Triple Pill for Hypertension: A Step Towards \u2018Minimally Disruptive Care\u2019 - Humain Healthcare:","headline":"FDA Approves Triple Pill for Hypertension: A Step Towards &#8216;Minimally Disruptive Care&#8217;","author":{"@id":"https:\/\/humainhealthcare.com\/fr\/author\/infohumainhealthcare-com\/#author"},"publisher":{"@id":"https:\/\/humainhealthcare.com\/fr\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/humainhealthcare.com\/wp-content\/uploads\/2025\/07\/image-3.png","width":1024,"height":1024},"datePublished":"2025-07-28T15:33:20+00:00","dateModified":"2025-07-28T15:33:21+00:00","inLanguage":"fr-FR","mainEntityOfPage":{"@id":"https:\/\/humainhealthcare.com\/fr\/fda-approves-triple-pill-for-hypertension-a-step-towards-minimally-disruptive-care\/#webpage"},"isPartOf":{"@id":"https:\/\/humainhealthcare.com\/fr\/fda-approves-triple-pill-for-hypertension-a-step-towards-minimally-disruptive-care\/#webpage"},"articleSection":"Geneva"},{"@type":"BreadcrumbList","@id":"https:\/\/humainhealthcare.com\/fr\/fda-approves-triple-pill-for-hypertension-a-step-towards-minimally-disruptive-care\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/humainhealthcare.com\/fr#listItem","position":1,"name":"Home","item":"https:\/\/humainhealthcare.com\/fr","nextItem":{"@type":"ListItem","@id":"https:\/\/humainhealthcare.com\/fr\/category\/geneva\/#listItem","name":"Geneva"}},{"@type":"ListItem","@id":"https:\/\/humainhealthcare.com\/fr\/category\/geneva\/#listItem","position":2,"name":"Geneva","item":"https:\/\/humainhealthcare.com\/fr\/category\/geneva\/","nextItem":{"@type":"ListItem","@id":"https:\/\/humainhealthcare.com\/fr\/fda-approves-triple-pill-for-hypertension-a-step-towards-minimally-disruptive-care\/#listItem","name":"FDA Approves Triple Pill for Hypertension: A Step Towards &#8216;Minimally Disruptive Care&#8217;"},"previousItem":{"@type":"ListItem","@id":"https:\/\/humainhealthcare.com\/fr#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/humainhealthcare.com\/fr\/fda-approves-triple-pill-for-hypertension-a-step-towards-minimally-disruptive-care\/#listItem","position":3,"name":"FDA Approves Triple Pill for Hypertension: A Step Towards &#8216;Minimally Disruptive Care&#8217;","previousItem":{"@type":"ListItem","@id":"https:\/\/humainhealthcare.com\/fr\/category\/geneva\/#listItem","name":"Geneva"}}]},{"@type":"Organization","@id":"https:\/\/humainhealthcare.com\/fr\/#organization","name":"Humain Healthcare","description":"International medical services provider in Barcelona offering personalized diagnosis, treatment coordination, and access to top specialists for global patients.","url":"https:\/\/humainhealthcare.com\/fr\/","telephone":"+34611975260","logo":{"@type":"ImageObject","url":"https:\/\/humainhealthcare.com\/wp-content\/uploads\/2025\/05\/WhatsApp-Image-2025-05-26-at-22.12.40_410869ab.jpg","@id":"https:\/\/humainhealthcare.com\/fr\/fda-approves-triple-pill-for-hypertension-a-step-towards-minimally-disruptive-care\/#organizationLogo","width":1024,"height":1024},"image":{"@id":"https:\/\/humainhealthcare.com\/fr\/fda-approves-triple-pill-for-hypertension-a-step-towards-minimally-disruptive-care\/#organizationLogo"},"sameAs":["https:\/\/www.facebook.com\/HumainHealthcareBarcelone","https:\/\/www.instagram.com\/humainhealthcare"]},{"@type":"Person","@id":"https:\/\/humainhealthcare.com\/fr\/author\/infohumainhealthcare-com\/#author","url":"https:\/\/humainhealthcare.com\/fr\/author\/infohumainhealthcare-com\/","name":"info@humainhealthcare.com","image":{"@type":"ImageObject","@id":"https:\/\/humainhealthcare.com\/fr\/fda-approves-triple-pill-for-hypertension-a-step-towards-minimally-disruptive-care\/#authorImage","url":"https:\/\/humainhealthcare.com\/wp-content\/litespeed\/avatar\/767cd8d416ab6b3ab02867bd8bcdbb54.jpg?ver=1790180516","width":96,"height":96,"caption":"info@humainhealthcare.com"}},{"@type":"WebPage","@id":"https:\/\/humainhealthcare.com\/fr\/fda-approves-triple-pill-for-hypertension-a-step-towards-minimally-disruptive-care\/#webpage","url":"https:\/\/humainhealthcare.com\/fr\/fda-approves-triple-pill-for-hypertension-a-step-towards-minimally-disruptive-care\/","name":"FDA Approves Triple Pill for Hypertension: A Step Towards \u2018Minimally Disruptive Care\u2019 - Humain Healthcare:","description":"Summary: The U.S. FDA has approved Widaplik, a polypill that combines telmisartan (an angiotensin II receptor blocker), amlodipine (a calcium channel blocker), and indapamide (a diuretic). This once-daily formulation aims to simplify hypertension treatment and improve adherence. \ud83d\udccc Clinical Evidence - A study published in *The Lancet* compared the polypill to various dual therapies. Results","inLanguage":"fr-FR","isPartOf":{"@id":"https:\/\/humainhealthcare.com\/fr\/#website"},"breadcrumb":{"@id":"https:\/\/humainhealthcare.com\/fr\/fda-approves-triple-pill-for-hypertension-a-step-towards-minimally-disruptive-care\/#breadcrumblist"},"author":{"@id":"https:\/\/humainhealthcare.com\/fr\/author\/infohumainhealthcare-com\/#author"},"creator":{"@id":"https:\/\/humainhealthcare.com\/fr\/author\/infohumainhealthcare-com\/#author"},"image":{"@type":"ImageObject","url":"https:\/\/humainhealthcare.com\/wp-content\/uploads\/2025\/07\/image-3.png","@id":"https:\/\/humainhealthcare.com\/fr\/fda-approves-triple-pill-for-hypertension-a-step-towards-minimally-disruptive-care\/#mainImage","width":1024,"height":1024},"primaryImageOfPage":{"@id":"https:\/\/humainhealthcare.com\/fr\/fda-approves-triple-pill-for-hypertension-a-step-towards-minimally-disruptive-care\/#mainImage"},"datePublished":"2025-07-28T15:33:20+00:00","dateModified":"2025-07-28T15:33:21+00:00"},{"@type":"WebSite","@id":"https:\/\/humainhealthcare.com\/fr\/#website","url":"https:\/\/humainhealthcare.com\/fr\/","name":"Humain Healthcare:","description":"Medical Treatment in\u00a0Barcelona","inLanguage":"fr-FR","publisher":{"@id":"https:\/\/humainhealthcare.com\/fr\/#organization"}}]},"og:locale":"fr_FR","og:site_name":"Humain Healthcare: - Medical Treatment in\u00a0Barcelona","og:type":"article","og:title":"FDA Approves Triple Pill for Hypertension: A Step Towards \u2018Minimally Disruptive Care\u2019 - Humain Healthcare:","og:description":"Summary: The U.S. FDA has approved Widaplik, a polypill that combines telmisartan (an angiotensin II receptor blocker), amlodipine (a calcium channel blocker), and indapamide (a diuretic). This once-daily formulation aims to simplify hypertension treatment and improve adherence. \ud83d\udccc Clinical Evidence - A study published in *The Lancet* compared the polypill to various dual therapies. Results","og:url":"https:\/\/humainhealthcare.com\/fr\/fda-approves-triple-pill-for-hypertension-a-step-towards-minimally-disruptive-care\/","og:image":"https:\/\/humainhealthcare.com\/wp-content\/uploads\/2025\/07\/twocaucasian.jpg","og:image:secure_url":"https:\/\/humainhealthcare.com\/wp-content\/uploads\/2025\/07\/twocaucasian.jpg","og:image:width":1216,"og:image:height":832,"article:published_time":"2025-07-28T15:33:20+00:00","article:modified_time":"2025-07-28T15:33:21+00:00","article:publisher":"https:\/\/www.facebook.com\/HumainHealthcareBarcelone","twitter:card":"summary_large_image","twitter:title":"FDA Approves Triple Pill for Hypertension: A Step Towards \u2018Minimally Disruptive Care\u2019 - Humain Healthcare:","twitter:description":"Summary: The U.S. FDA has approved Widaplik, a polypill that combines telmisartan (an angiotensin II receptor blocker), amlodipine (a calcium channel blocker), and indapamide (a diuretic). This once-daily formulation aims to simplify hypertension treatment and improve adherence. \ud83d\udccc Clinical Evidence - A study published in *The Lancet* compared the polypill to various dual therapies. Results","twitter:image":"https:\/\/humainhealthcare.com\/wp-content\/uploads\/2025\/07\/twocaucasian.jpg"},"aioseo_meta_data":{"post_id":"371638","title":null,"description":null,"keywords":null,"keyphrases":{"focus":{"keyphrase":"","score":0,"analysis":{"keyphraseInTitle":{"score":0,"maxScore":9,"error":1}}},"additional":[]},"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":"","og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"BlogPosting","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":"-1","robots_max_videopreview":"-1","robots_max_imagepreview":"large","priority":null,"frequency":"default","local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2025-07-28 15:33:21","updated":"2025-09-26 14:07:59","seo_analyzer_scan_date":null,"focus_keyword":null,"additional_keywords":null,"truseo_locale":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/humainhealthcare.com\/fr\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/humainhealthcare.com\/fr\/category\/geneva\/\" title=\"Geneva\">Geneva<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tFDA Approves Triple Pill for Hypertension: A Step Towards \u2018Minimally Disruptive Care\u2019\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/humainhealthcare.com\/fr"},{"label":"Geneva","link":"https:\/\/humainhealthcare.com\/fr\/category\/geneva\/"},{"label":"FDA Approves Triple Pill for Hypertension: A Step Towards &#8216;Minimally Disruptive Care&#8217;","link":"https:\/\/humainhealthcare.com\/fr\/fda-approves-triple-pill-for-hypertension-a-step-towards-minimally-disruptive-care\/"}],"_links":{"self":[{"href":"https:\/\/humainhealthcare.com\/fr\/wp-json\/wp\/v2\/posts\/371638","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/humainhealthcare.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/humainhealthcare.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/humainhealthcare.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/humainhealthcare.com\/fr\/wp-json\/wp\/v2\/comments?post=371638"}],"version-history":[{"count":1,"href":"https:\/\/humainhealthcare.com\/fr\/wp-json\/wp\/v2\/posts\/371638\/revisions"}],"predecessor-version":[{"id":371640,"href":"https:\/\/humainhealthcare.com\/fr\/wp-json\/wp\/v2\/posts\/371638\/revisions\/371640"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/humainhealthcare.com\/fr\/wp-json\/wp\/v2\/media\/371639"}],"wp:attachment":[{"href":"https:\/\/humainhealthcare.com\/fr\/wp-json\/wp\/v2\/media?parent=371638"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/humainhealthcare.com\/fr\/wp-json\/wp\/v2\/categories?post=371638"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/humainhealthcare.com\/fr\/wp-json\/wp\/v2\/tags?post=371638"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}